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SUMMARY
Preclinical studies have shown benefit of apolipoprotein A-I (apoA-I)/high-density lipoprotein (HDL) raising in atherosclerosis; however, this has not yet translated into a successful clinical therapy. Our studies demonstrate that apoA-I raising is more effective at reducing early-stage atherosclerosis than late-stage disease, indicating that the timing of HDL raising is a critical factor in its atheroprotective effects. To have not yet shown benefit on clinical endpoints (9) (10) (11) or imaging assessment of atherosclerotic plaque (12) (13) (14) . Recently, a third CETP inhibitor (evacetrapib) was discontinued due to lack of efficacy. Off-target pharmacological effects such as increased systolic blood pressure have been reported, yet it invites reflection on how to reconcile the neutral results of the clinical trials with the mountain of evidence supporting the atheroprotective benefits of HDL.
There are notable differences in the timing of the HDL/apoA-I interventions between the preclinical studies and the recent clinical trials (7, (12) (13) (14) . that may not be amenable to cholesterol efflux. There is also evidence that HDL functionality is compromised in aged patients (20, 21) with coronary artery disease (22, 23) .
The timing of HDL/apoA-I raising may therefore be critical for HDL to exert its maximum beneficial effects.
We report that apoA-I raising, when initiated in young animals with early-stage disease, decreased atheroma progression and improved plaque composition. By contrast, these beneficial effects were greatly attenuated in older mice with late-stage disease, and HDL functionality was compromised. Our findings may explain the disparity between the preclinical studies and recent human trials using HDL-raising therapies.
METHODS
An expanded Methods section is available in the Supplemental Appendix. Morton et al.
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ANIMAL PROTOCOLS AND TREATMENTS. L a t e -s t a g e p l a q u e m o d e l . Eight-week-old apolipoprotein E-deficient (apoE SMC ¼ smooth muscle cell.
Stage-Specific Effects of ApoA-I in Atherosclerosis post-infusion, which fell quickly to 11% of the maximum by 24 h. Peak HDL cholesterol was 61.9 mg/dl 8 h post-infusion, which then declined more gradually than apoA-I, reaching baseline 72 h post-infusion.
There were no differences in total cholesterol or HDL cholesterol between apoA-I-and saline-infused mice in plasma collected 48 h after the final apoA-I infusion (Supplemental Table 1 ). Human apoA-I was detected in the plasma and the aortic sinus plaques saline-and apoA-I-infused mice ( Figure 1C ). There were also no differences between saline-and apoA-I-infused mice in plaque smooth muscle cell (SMC) Morton et al.
content, indicating no improvement in plaque stability with apoA-I. Table 1 ). Human apoA-I was detected in the plaque of the LVApoAI-infused mice only (Supplemental Figure 2 ).
Despite sustained, long-term apoA-I raising, lentiviral gene transfer had no effect on aortic sinus atheroma area when delivered to mice with established atherosclerosis ( Figure 2A ). There were no changes in plaque composition, including macrophage content, extracellular lipid content or SMC content between lentiviral LVGFP control and LVApoAI mice ( Figures 2B to 2D ). These results are consistent with the largely neutral effects found in our long-term apoA-I infusion study.
ApoA-I INFUSIONS REDUCE ATHEROSCLEROTIC PLAQUE SIZE AND IMPROVE PLAQUE STABILITY IN
MICE WITH EARLY-STAGE DISEASE. ApoA-I infusions had no effect on total cholesterol or HDL level (16) . All apoA-I-infused mice and no baseline or saline-infused mice had detectable human apoA-I Figure 1 .
Stage-Specific Effects of ApoA-I in Atherosclerosis (Supplemental Table 1 Morton et al.
Stage-Specific Effects of ApoA-I in Atherosclerosis from baseline to sacrifice ( Figures 5C and 5D ). Figure 1 .
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However, 16 weeks of apoA-I infusions were unable to change either plaque macrophage or SMC content, compared with saline-infused controls. We Morton et al.
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Stage-Specific Effects of ApoA-I in Atherosclerosis (25) , where 12 weeks of apoA-I raising following 6 months of HFD had no effect on aortic sinus plaque area.
Although early fatty streaks may be reversible (19) , late-stage plaques undergo gross anatomic changes that may make resolution difficult. In addition, advanced atheromas have areas of ischemia that promote neointimal vascularization from the supporting vasa vasorum (26) . HDL has multifunctional effects on angiogenesis such that it stimulates ischemia-mediated angiogenesis (27) , but yet inhibits inflammatory-driven neovascularization (27) .
Advanced plaque neovascularization is driven by both hypoxia and inflammation. This may explain why we found no change in adventitial neovessel volume with apoA-I infusions.
The lack of benefit of apoA-I infusions on descending thoracic aorta plaques, which were fatty streaks at baseline, cannot be explained by a mistiming of the plaque stage of apoA-I intervention.
Mice in the late-stage model were 26 weeks old at Morton et al.
Stage-Specific Effects of ApoA-I in Atherosclerosis following dalcetrapib treatment (11) . We therefore achieved an apoA-I level above normal human physiological levels.
This study infused lipid-free apoA-I into mice rather than reconstituted HDL (apoA-I complexed with phospholipid) as was infused in clinical intervention studies (7, 8, 12) . Infused apoA-I rapidly acquires lipid from the plasma to form a very similar discoidal HDL particle (32) . TRANSLATIONAL OUTLOOK: In the future, preclinical studies using HDL-modulating therapies should take into consideration the biology of the humans to whom the therapy is aimed. An improved understanding of the mechanisms underlying HDL dysfunction will assist with the development of strategies that overcome this impairment so that HDL functionality is maintained with aging and disease.
